Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRYAB | P02511 | 4/20 | 0.78 |
| ▸ | FNTA | P49354 | 3/20 | 0.76 |
| ▸ | FNTB | P49356 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.65 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | PIN1 | Q13526 | 4/20 | 0.59 |
| ▸ | PTGES | O14684 | 1/20 | 0.59 |
| ▸ | PREP | P48147 | 1/20 | 0.59 |
| ▸ | CRYAA | P02489 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428555 | 0.87 | CRYAB (0.76) | CRYABFNTAFNTBMEN1PLA2G1B | |
| Clavarinone SCHEMBL606234 | 0.86 | FNTA (1.00) | CRYABFNTAFNTBMEN1PLA2G1B | |
| Clavarinone SCHEMBL606233 | 0.86 | FNTA (1.00) | CRYABFNTAFNTBMEN1PLA2G1B | |
| Lucidumol A SCHEMBL28150374 | 0.86 | ACHE (0.59) | CRYABFNTAFNTBMEN1PLA2G1B | |
| Lucidumol A SCHEMBL28150372 | 0.86 | ACHE (0.59) | CRYABFNTAFNTBMEN1PLA2G1B | |
| SCHEMBL17431812 | 0.86 | CRYAB (0.71) | CRYABFNTAFNTBMEN1PLA2G1B | |
| SCHEMBL17431762 | 0.85 | CRYAB (0.77) | CRYABFNTAFNTBMAPTACHE | |
| SCHEMBL29692186 | 0.85 | CRYAB (0.77) | CRYABFNTAFNTBMAPTACHE | |
| SCHEMBL17428538 | 0.85 | FNTA (0.67) | CRYABFNTAFNTBMAPTACHE | |
| SCHEMBL17874600 | 0.83 | FNTA (0.79) | CRYABFNTAFNTBMEN1PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522935-B2 | Commands and method of treating cancer via RHO pathway | DM INTELLIGENCE MEDICINE LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-9522935-B2 | Commands and method of treating cancer via RHO pathway | DM INTELLIGENCE MEDICINE LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20160009756-A1 | Commands and method of treating cancer via RHO pathway | Xie, Weidong (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160009756-A1 | Commands and method of treating cancer via RHO pathway | Xie, Weidong (CA) | 2016-01-14 | — | — | US | disclosed |
| WO-2014117710-A1 | COMMANDS AND METHOD OF TREATING CANCER VIA RHO PATHWAY | LIU XIN (CN) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009756-A1 | Commands and method of treating cancer via RHO pathway | RHOA, RHOT2, ROCK1 | CRYAB 2144/4885FNTA 120/4885FNTB 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.